Patriot Financial Group Insurance Agency LLC lowered its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 16.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,194 shares of the biopharmaceutical company’s stock after selling 1,645 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Bristol-Myers Squibb were worth $435,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Staley Capital Advisers Inc. increased its stake in shares of Bristol-Myers Squibb by 0.3% in the first quarter. Staley Capital Advisers Inc. now owns 6,962 shares of the biopharmaceutical company’s stock valued at $379,000 after buying an additional 24 shares during the period. Shayne & CO. LLC increased its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Shayne & CO. LLC now owns 4,017 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 27 shares during the period. Founders Capital Management LLC increased its stake in shares of Bristol-Myers Squibb by 0.7% in the first quarter. Founders Capital Management LLC now owns 4,097 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 29 shares during the period. Physicians Financial Services Inc. increased its stake in shares of Bristol-Myers Squibb by 0.4% in the first quarter. Physicians Financial Services Inc. now owns 9,929 shares of the biopharmaceutical company’s stock valued at $540,000 after buying an additional 39 shares during the period. Finally, Pettyjohn Wood & White Inc. increased its stake in shares of Bristol-Myers Squibb by 0.5% in the first quarter. Pettyjohn Wood & White Inc. now owns 7,825 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 40 shares during the period. 68.78% of the stock is owned by institutional investors and hedge funds.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 0.66% on Wednesday, hitting $59.25. 1,221,220 shares of the stock traded hands. The stock has a 50 day moving average of $56.20 and a 200 day moving average of $55.23. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $60.45. The company has a market cap of $97.17 billion, a PE ratio of 21.64 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $0.69 earnings per share. Equities analysts anticipate that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.65%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.

WARNING: “Patriot Financial Group Insurance Agency LLC Has $435,000 Position in Bristol-Myers Squibb Company (BMY)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/08/30/patriot-financial-group-insurance-agency-llc-has-435000-position-in-bristol-myers-squibb-company-bmy.html.

Several equities research analysts recently weighed in on BMY shares. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price target for the company. in a research report on Wednesday, May 3rd. Jefferies Group LLC reissued a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Thursday, July 27th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target for the company in a research report on Monday, June 5th. Finally, BidaskClub downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, July 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $62.31.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.